

FUNCTIONAL AND MORPHOLOGICAL STATE OF SMALL INTESTINAL CELLS IN PATIENTS WITH RHEUMATOID ARTHRITIS

Saidova Muxabbat Muxiddinovna
Boltaeva Mayram Miralievna

*Bukhara State Medical Institute. Bukhara, Uzbekistan. Author Email
baltayevamaryam96@gmail.com*

Abstract: *This review is devoted to characterizing the cause of the risk of damage to the small intestine in patients with rheumatoid arthritis. One of the urgent problems of modern medicine is the defeat of the small intestine in rheumatoid arthritis. The issues of prevalence and risk factors of chronic gastrointestinal disease are considered. The small intestine is affected in rheumatoid arthritis more often than it is diagnosed. As a result, early diagnosis of lesions of the small intestine in patients with rheumatoid arthritis has an important clinical and prognostic value. Possible morphological variants and mechanisms of damage to the small intestine are also considered. In rheumatoid arthritis, the occurrence of a chronic disease of the gastrointestinal tract depends primarily on the duration of the disease and the nature of the inflammatory process. These data are fully confirmed at the present time. The problem of damage to the small intestine in rheumatoid arthritis is poorly understood and requires further research.*

Key words: *Small intestine, rheumatoid arthritis, dyspepsia, gastrointestinal tract, chronic enteritis.*

Rheumatic diseases are the oldest human pathology, and are considered the most common ailments of the XXI century. In recent decades, there has been some progress in the field of theoretical and clinical rheumatology. According to E.A. Galushko and E.L. Nasonov rheumatic diseases include more than 80 diseases and syndromes [10].

Rheumatoid arthritis (RA) is an autoimmune disease characterized by the development of chronic destructive polyarthritis with frequent involvement of other systems in the pathological process. Extra-articular systemic lesions in RA can have a serious impact on the prognosis of the disease [3,14].

Pathology of the organs of the small intestine is detected in 13-62% of patients suffering from RA [7] and occupies an important place among the extra-articular manifestations of this disease.

Chronic enteritis in patients with rheumatoid arthritis develops primarily as a manifestation of systemic disorders characteristic of RA (lesion of the microvasculature, lymphoplasmacytic cell reactions), and the stages characteristic of enteritis of any origin occur, namely, superficial, chronic enteritis. On the other hand, damage to the mucous membrane of the upper small intestine is exacerbated by the use of non-steroidal anti-inflammatory drugs and glucocorticosteroids.

Morphological manifestations of active enteritis were characterized by the fact that against the background of a pronounced inflammatory infiltration of the mucous membrane of enteritis by lymphocytes and plasmocytes, a large number of neutrophils appeared in the infiltrate and integumentary epithelium. Most often, when taking drugs of this class, adverse reactions from the gastrointestinal tract occur. Adverse events (AEs) range from moderate symptoms such as dyspepsia, heartburn and abdominal discomfort to more serious events associated with life-threatening complications. The mucous membrane (CO) has certain protective mechanisms; when taking NSAIDs, the functioning of most of these mechanisms is disrupted [8]. Intestinal pathology in RA is considered in the literature in terms of side effects of basic therapy [1,4]. Functional and structural features with different disease activity remain less studied, their role in maintaining autoimmune systemic inflammation has not been established. The role of biogenic amines and peptide hormones produced by the diffuse endocrine system (DES) in the regulation of motility, absorption in the small intestine, nociception, tissue trophism, and induction of the inflammatory process is widely discussed. Some works have been devoted to the study of the concentration of neuropeptides in the synovial membrane and blood plasma in RA, the quantitative density of the DES components of the intestinal mucosa in RA and the relationship with the activity of the autoimmune process have not been studied.

The role of intestinal pathology in RA remains unexplored. Changes in the intestine may be a consequence of the development and manifestation of immune inflammation and may be an inducer of a pathological process during which the body is sensitized to autoflora components. Intestinal microecology has a significant impact on homeostasis, being directly involved in the formation of the immune response. Data have been published that patients with RA have defective circulating T cells (Treg) [8], an increased titer of Th17 cells in plasma and synovial fluid is observed, the role and significance of which is being studied. It is possible that dysregulatory and dysbiotic disorders of the intestine can lead to impaired immune tolerance, being one of the triggers for a systemic response.

The prognosis is especially unfavorable in patients with RA with systemic manifestations: generalized vasculitis, rheumatoid nodules, lymphadenopathy, damage to the lungs, heart, liver, kidneys and other organs and systems. Among the extra-articular manifestations of RA, lesions of the small intestine are the least studied, although the most severe process is well known - intestinal amyloidosis, which occurs in 11% of patients and is usually combined with amyloidosis of other internal organs [11].

Patients with RA were noted to have impaired motility and secretory function of the intestine [12,15], the development of chronic enteritis [13], which is three times higher than its occurrence in the general population, as well as the frequent occurrence of mucosal ulcers [2,10]. A number of researchers considered the nature of these changes in the context of the systemic nature of rheumatoid inflammation,

believing that immune disorders are the basis of enteritis. Nevertheless, the question of the specific gravity, on the one hand, of immune disorders in the intestine caused by the underlying disease, and, on the other hand, of the mucosal-damaging effects of drugs that patients are forced to take constantly, is still debatable. In the literature of recent years, the main emphasis in the development of intestinal disorders is on drug enteropathy. The pathogenesis of these enteropathies has not been fully deciphered and probably should not be considered outside of the processes that may be due to general immunopathological patterns inherent in RA as a systemic disease. Moreover, at present, a position is postulated that represents any chronic enteritis as an immune pathology proceeding according to the standard scheme [6].

In order to achieve remission and relapse-free course of RA, as well as to prevent the development of irreversible deformities of joint deformities, patients are forced to constantly take basic drugs. In combination with it, non-steroidal anti-inflammatory drugs (NSAIDs) and quite often glucocorticoids (GC) are prescribed to suppress inflammation in the joints, eliminate pain in them, morning stiffness, poor general health. Such therapy, started from the moment of RA diagnosis, can create prerequisites for the correction of immunoregulatory disorders, affect the course of the disease, slow down its progression, and provide symptomatic [6].

However, the constant use of NSAIDs, immunosuppressants and GC causes a high level of damage to the small intestine. It is well known from the literature data that NSAIDs, by inhibiting the production of prostaglandins (PG), burns the resistance of the intestinal mucosa to the aggressive effects of hydrochloric acid and pepsin, leads to the development of enteropathy, which, in some cases, can threaten the lives of patients. Reduction of pain and inflammation in the joints in patients with RA in the treatment of NSAIDs is often achieved at the cost of significant side effects from the digestive tract. So, more often than in the general population, erosive and ulcerative lesions develop. The risk of NSAIDs - enteropathy increases with simultaneous GC therapy. The use of synthetic analogues of PG did not lead to complete elimination, although it did reduce the incidence of intestinal lesions. The role of intestinal pathology in RA remains unexplored. Changes in the intestine may be a consequence of the development and manifestation of immune inflammation and may be an inducer of a pathological process during which the body is sensitized to autoflora components. Intestinal microecology has a significant impact on homeostasis, being directly involved in the formation of the immune response. Data have been published that patients with RA have defective circulating T cells (Treg) [9], an increased titer of Th17 cells in plasma and synovial fluid [5,] is observed, the role and significance of which is being studied. It is possible that dysregulatory and dysbiotic disorders of the intestine can lead to impaired immune tolerance. ranciency, being one of the triggers of a systemic response.

It is currently difficult to say which is primary - RA or bowel changes. Obviously, there is a combination of violations of the structural and functional characteristics of

the joints and intestines on against the background of a systemic imbalance of DES components. Against the background of an imbalance of hormones and neurotransmitters, inflammatory-dystrophic mucous membranes develop, which facilitate the penetration of antibodies.

Microbial and viral antigens of the intestinal ecosystem, in turn, cause endogenous intoxication, initiate immune inflammation, and exacerbate the course of RA.

REFERENCES:

1. Axmatovna M. S. et al. Peculiarities of the morphophenotype and characteristics of the physical performance of young football players and their relationship with the gaming amplitude //Academicia: an international multidisciplinary research journal. – 2021. – Т. 11. – №. 2. – С. 1381-1388.

2. Boltaeva M. M. Treatment of Arterial Hypertension in Elderly Patients and Senile Age Group // Spanish Journal of Innovation and Integrity –2022.– Vol.05, P 346-349.

3. Hickson LJ, Crowson CS, Gabriel SE, et al. Development of reduced kidney function in rheumatoid arthritis. Am J Kidney Dis. 2014;63:206-13. doi: 0.1053/j.ajkd.2013.08.010

4. Kholmurodovich U. F. Damage to the digestive system when using non-steroidal anti-inflammatory drugs //European journal of modern medicine and practice. – 2022. – Т. 2. – №. 1. – С. 6-16.

5. Lubberts E. Th17 cytokines and arthritis // Semin. Immunopathol. – 2017. – Vol. 32, № 1. – P. 43–53.

6. Miralievna B. M. RHEUMATOID ARTHRITIS: PROBLEMS OF REMISSION AND RESISTANCE TO THERAPY // EURASIAN JOURNAL OF TECHNOLOGY AND INNOVATION. – 2023. – Vol. 1. – P. 65-69.

7. Turesson C. Incidence and predictors of severe extraarticular disease manifestations in an early rheumatoid arthritis inception cohort // Ann. Rheum. Dis. – 2017. – Vol. 66. – P. 1543–4.

8. Zanin-Zhorov A. Protein kinase C- θ mediates negative feedback on regulatory T cell function // Science. – 2015. – Vol. 328. – P. 372–376.

9. Zanin-Zhorov A. Protein kinase C- θ mediates negative feedback on regulatory T cell function // Science. – 2014. – Vol. 328. – P. 372–376.

10. Галушко ЕА, Насонов ЕЛ. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018;46(1):32–39. doi:10.18786/2072-0505-2018-46- 1-32-39.

11. Джаббарова М. Б. и др. Сравнительная характеристика лекарственных средств, используемых для лечения хронических гепатитов и цирроза печени //Новый день в медицине. – 2019. – №. 4. – С. 151-154.

12. Джаббарова М. Б., Раджабова Г. Б. ДИАГНОСТИКА НАРУШЕНИЙ ДЫХАНИЯ В НОЧНЫЕ ЧАСЫ И РЕСПИРАТОРНАЯ ТЕРАПИЯ ПАЦИЕНТОВ С ХОБЛ //Биология и интегративная медицина. – 2022. – №. 2 (55). – С. 84-94.

13. Мустафаева Ш. А. Функционально-Морфологическое Состояние Клеток Почек У Больных Ревматоидным Артритом //AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI. – 2022. – Т. 1. – №. 4. – С. 22-27.

14. Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология. Национальное руководство. Под. ред.Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2018; с. 290-331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis.In: Rheumatology. National Guide.

15. Саидова М. М. ОЦЕНКА ПАРАМЕТРОВ ТОЛЩИНЫ ИНТИМА-МЕДИА СОННЫХ АРТЕРИЙ КАК РАННЕГО ПРЕДИКТОРА РАЗВИТИЯ АТЕРОСКЛЕРОЗА У БОЛЬНЫХ РЕВМАТОИДНЫМ АРТРИТОМ //Журнал кардиореспираторных исследований. – 2022. – Т. 3. – №. 1.

16. Umarov F. K. The Effect of Pharmacological Agents on the Liver //Research Journal of Trauma and Disability Studies. – 2022. – Т. 1. – №. 10. – С. 4-16.

17. Toyirovna, Y. S. (2022). The importance of integrative and creative capabilities of students of medical institutes. Барқарорлик ва Етакчи Тадқиқотлар онлайн илмий журнали, 2(1), 450-462.

18. Toirovna, Y. S. (2022). Integrative education of university students. Барқарорлик ва етакчи тадқиқотлар онлайн илмий журнали, 2(3), 73-77.